Graft Versus Host Disease

Graft versus host disease (GVHD) is a complication that can develop after a person has had a bone marrow or stem cell transplant. In the disease, the host body comes under attack from the donated cells.
What is Graft Versus Host Disease (GVHD)?

Graft versus host disease (GVHD) is a complication that can develop after a person has had a bone marrow or stem cell transplant. In the disease, the host body comes under attack from the donated cells.

Read More

Overview

Feature Articles

Latest Graft Versus Host Disease News and Research

Clinical characteristics of immunocompromised patients infected with the SARS-CoV-2 Omicron variant

Clinical characteristics of immunocompromised patients infected with the SARS-CoV-2 Omicron variant

Roswell Park experts to share latest advances in the treatment of blood-related cancers

Roswell Park experts to share latest advances in the treatment of blood-related cancers

NK cells combined with bispecific antibody achieve effective responses in patients with lymphoma

NK cells combined with bispecific antibody achieve effective responses in patients with lymphoma

Partially matched blood cells could help cure people with both cancer and HIV

Partially matched blood cells could help cure people with both cancer and HIV

'Humanized' mouse model beats current approaches for finding the best organ donor

'Humanized' mouse model beats current approaches for finding the best organ donor

Researchers conduct first-in-man clinical trial for new stem cell technology

Researchers conduct first-in-man clinical trial for new stem cell technology

Antiviral T cells safe, effective as off-the-shelf therapy for painful complication after stem cell transplants

Antiviral T cells safe, effective as off-the-shelf therapy for painful complication after stem cell transplants

Researchers develop an effective strategy to fight against chronic myelomonocytic leukemia

Researchers develop an effective strategy to fight against chronic myelomonocytic leukemia

Clinical investigators present abstracts on hematological malignancies at ASH Annual Meeting and Exposition

Clinical investigators present abstracts on hematological malignancies at ASH Annual Meeting and Exposition

Immune mechanism responsible for adverse inflammatory reactions after stem cell transplant identified

Immune mechanism responsible for adverse inflammatory reactions after stem cell transplant identified

New Independent Research Organization status awarded to Anthony Nolan and ANRI

New Independent Research Organization status awarded to Anthony Nolan and ANRI

FDA awards six clinical trial research grants to enhance development of therapies for rare diseases

FDA awards six clinical trial research grants to enhance development of therapies for rare diseases

Umbilical cord blood safely and effectively treats children with rare genetic disorders

Umbilical cord blood safely and effectively treats children with rare genetic disorders

Ruxolitinib shows promise in severe COVID-19

Ruxolitinib shows promise in severe COVID-19

Dana-Farber launches clinical test of blood cancer drug in COVID-19 patients

Dana-Farber launches clinical test of blood cancer drug in COVID-19 patients

Harmful genetic mutations in healthy donors' stem cells may create problems in AML patients

Harmful genetic mutations in healthy donors' stem cells may create problems in AML patients

Temperature fluctuations could give early indications of graft-versus-host disease

Temperature fluctuations could give early indications of graft-versus-host disease

Stem cell transplant following treatment with PD-1 inhibitor is safe, effective for patients with Hodgkin lymphoma

Stem cell transplant following treatment with PD-1 inhibitor is safe, effective for patients with Hodgkin lymphoma

Adding venetoclax to transplant conditioning regimen shows promise in patients with myeloid cancers

Adding venetoclax to transplant conditioning regimen shows promise in patients with myeloid cancers

Adding post-transplant chemotherapy to standard treatment improves remission of allogeneic transplant patients

Adding post-transplant chemotherapy to standard treatment improves remission of allogeneic transplant patients